Results 101 to 110 of about 255,378 (313)

TOR Mutations Confer Rapamycin Resistance by Preventing Interaction with FKBP12-Rapamycin [PDF]

Journal of Biological Chemistry, 1995
The antifungal, immunosuppressive compound rapamycin arrests the cell cycle in G1 in both yeast cells and T-lymphocytes. Previous genetic studies in yeast identified mutations in three genes, FPR1 (FKBP12), TOR1, and TOR2, which confer rapamycin resistance, and genetic findings implicated the TOR proteins as direct targets of FKBP12-rapamycin ...
M C, Lorenz, J, Heitman
openaire   +2 more sources

β‐Catenin/c‐Myc Axis Modulates Autophagy Response to Different Ammonia Concentrations

Advanced Biology, Volume 9, Issue 3, March 2025.
Ammonia, detoxified by the liver into urea and glutamine, impacts autophagy differently at varying levels. Low ammonia activates autophagy via c‐Myc and β‐catenin, while high levels suppress it. Using Huh7 cells and Spf‐ash mice, c‐Myc's role in cytoprotective autophagy is revealed, offering insights into hyperammonemia and potential therapeutic ...
S. Sergio, B. Spedicato, G. Corallo, A. Inguscio, M. Greco, D. Musarò, D. Vergara, A. F. Muro, G. De Sabbata, L. R. Soria, N. Brunetti Pierri, M. Maffia   +11 more
wiley   +1 more source

Role of mTOR signaling in tumor microenvironment. An overview [PDF]

, 2018
The mammalian target of rapamycin (mTOR) pathway regulates major processes by integrating a variety of exogenous cues, including diverse environmental inputs in the tumor microenvironment (TME).
Bazzichetto, Chiara, Bria, Emilio, Ciuffreda, L., Cognetti, F., COGNETTI, FRANCESCO, Conciatori, Fabiana, Falcone, I., Milella, M., Pilotto, Sara   +8 more
core   +2 more sources

Spleen‐Targeting Biomimetic Hybrid Nanocarriers for Systemic Immune Reprogramming in Colitis: RBC Membrane Vesicle‐Fused Lipid Nanoparticles

Advanced Functional Materials, EarlyView.
A spleen‐targeting hybrid nanoplatform (RBCMV‐LNP‐RP) harnessing erythrophagocytosis mimics senescent red blood cell clearance to achieve spleen‐specific delivery of rapamycin. This biomimetic system enables selective accumulation in splenic macrophages, orchestrating systemic immune reprogramming and promoting mucosal healing in an inflammatory bowel ...
Jun Kwon, Hee Su Sohn, Jong Sang Yoon, So Won Jeon, Hee Gyeong Ko, Min‐Ho Kang, Jisun Lee, Jae‐Hwan Nam, Louis T. Merriam, Edy Y. Kim, Han Young Kim   +10 more
wiley   +1 more source

Pathogenic Role of mTORC1 and mTORC2 in Pulmonary Hypertension. [PDF]

, 2018
Concentric lung vascular wall thickening due to enhanced proliferation of pulmonary arterial smooth muscle cells is an important pathological cause for the elevated pulmonary vascular resistance reported in patients with pulmonary arterial hypertension ...
Ayon, Ramon J, Balistrieri, Angela, Black, Stephen M, Chen, Jiwang, Desai, Ankit A, Garcia, Joe GN, Gu, Yali, Makino, Ayako, Rischard, Franz, Song, Shanshan, Tang, Haiyang, Vanderpool, Rebecca, Vinjamuri, Sujana, Wang, Jian, Wang, Ziyi, Wu, Kang, Yuan, Jason X-J, Zhang, Qian, Zhou, Guofei   +18 more
core   +1 more source

Premature recruitment of oocyte pool and increased mTOR activity in Fmr1 knockout mice and reversal of phenotype with rapamycin. [PDF]

, 2018
While mutations in the fragile X mental retardation-1 (FMR1) gene are associated with varying reproductive outcomes in females, the effects of a complete lack of FMR1 expression are not known.
Ascano, M, Mok-Lin, E, Rosenwaks, Z, Serganov, A, Tuschl, T, Williams, Z   +5 more
core   +2 more sources

Computational Modeling Meets 3D Bioprinting: Emerging Synergies in Cardiovascular Disease Modeling

Advanced Healthcare Materials, EarlyView.
Emerging advances in three‐dimensional bioprinting and computational modeling are reshaping cardiovascular (CV) research by enabling more realistic, patient‐specific tissue platforms. This review surveys cutting‐edge approaches that merge biomimetic CV constructs with computational simulations to overcome the limitations of traditional models, improve ...
Tanmay Mukherjee, Mehdi Salar Amoli, Sarah Rezapourdamanab, Lama Rita El Shammas, Martin L. Tomov, Emilio A. Mendiola, Vahid Serpooshan, Reza Avazmohammadi   +7 more
wiley   +1 more source

Cancer prevention with rapamycin

Oncotarget, 2023
Rapamycin (sirolimus) and other rapalogs (everolimus) are anti-cancer and anti-aging drugs, which delay cancer by directly targeting pre-cancerous cells and, indirectly, by slowing down organism aging. Cancer is an age-related disease and, figuratively, by slowing down time (and aging), rapamycin may delay cancer.
openaire   +2 more sources

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

Advanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang, Jingguo Qu, Tonghuan Xiao, Xinyang Han, Michael Tin‐Cheung Ying   +4 more
wiley   +1 more source

Genome-wide association study for biomarker identification of Rapamycin and Everolimus using a lymphoblastoid cell line system

Frontiers in Genetics, 2013
The mammalian target of rapamycin (mTOR) inhibitors, a set of promising potential anti-cancer agents, has shown response variability among individuals.
Jing eJiang, Brooke L Fridley, Qiping eFeng, Ryan eAbo, Abra eBrisbin, Anthony eBatzler, Gregory eJenkins, Pamela eLong, Liewei eWang   +8 more
doaj   +1 more source